Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV, FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that new
(Financial Post, 2025-10-16T08:04:58Z)